Repeating of local therapy of distant metastases increases overall survival in patients with synchronous metastasized rectal cancer—a monocentric analysis

[1]  J. Figueras,et al.  Oncological strategies for locally advanced rectal cancer with synchronous liver metastases, interval strategy versus rectum first strategy: a comparison of short-term outcomes , 2018, Clinical and Translational Oncology.

[2]  K. Brennan,et al.  Pulmonary Metastasectomy for Colorectal Cancer: Predictors of Survival in Routine Surgical Practice. , 2018, The Annals of thoracic surgery.

[3]  H. Friess,et al.  Meta‐analysis of outcomes following resection of the primary tumour in patients presenting with metastatic colorectal cancer , 2018, The British journal of surgery.

[4]  S. Truant,et al.  Repeated Resections of Hepatic and Pulmonary Metastases from Colorectal Cancer Provide Long-Term Survival , 2018, World Journal of Surgery.

[5]  G. Smailytė,et al.  Improved perioperative care is associated with improved long-term survival in colorectal cancer , 2018, International Journal of Colorectal Disease.

[6]  N. Francis,et al.  Can the combination of laparoscopy and enhanced recovery improve long-term survival after elective colorectal cancer surgery? , 2018, International Journal of Colorectal Disease.

[7]  Yingcai Zhang,et al.  Laparoscopic versus open liver resection for colorectal liver metastases: a systematic review. , 2017, The Journal of surgical research.

[8]  W. Eisterer,et al.  Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer , 2017, Strahlentherapie und Onkologie.

[9]  V. Jooste,et al.  Time trends in colorectal cancer early postoperative mortality. A French 25-year population-based study , 2017, International Journal of Colorectal Disease.

[10]  T. Treasure,et al.  Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017 .

[11]  C. Hallemeier,et al.  The role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis. , 2017, Journal of gastrointestinal oncology.

[12]  J. Ledermann,et al.  Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017, Journal of the National Cancer Institute.

[13]  Y. Yamada,et al.  Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer , 2017, Visceral Medicine.

[14]  A. Dennison,et al.  Repeat hepatectomy is independently associated with favorable long‐term outcome in patients with colorectal liver metastases , 2017, Cancer Medicine.

[15]  J. Schirren,et al.  Repeat resection for recurrent pulmonary metastasis of colorectal cancer , 2017, Langenbeck's Archives of Surgery.

[16]  P. Lian,et al.  Role of pelvic radiotherapy for locally advanced rectal cancer and synchronous unresectable distant metastases. , 2016, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[17]  Yuhree Kim,et al.  Combined resection and RFA in colorectal liver metastases: stratification of long-term outcomes. , 2016, The Journal of surgical research.

[18]  A. Mussi,et al.  Long-term results of percutaneous radiofrequency ablation of pulmonary metastases: a single institution experience. , 2016, Interactive cardiovascular and thoracic surgery.

[19]  A. Ferko,et al.  Neoadjuvant chemoradiotherapy of rectal carcinoma , 2016, Strahlentherapie und Onkologie.

[20]  J. Fütterer,et al.  Short term and long term results of patients with colorectal liver metastases undergoing surgery with or without radiofrequency ablation. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  F. Fischbach,et al.  Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy , 2016, Strahlentherapie und Onkologie.

[22]  T. Gruenberger,et al.  Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  E. Van Cutsem,et al.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R. Goldin,et al.  The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review , 2013, Clinical & Experimental Metastasis.

[25]  F. Aucejo,et al.  Complementary Use of Resection and Radiofrequency Ablation for the Treatment of Colorectal Liver Metastases: An Analysis of 395 Patients , 2013, World Journal of Surgery.

[26]  Luigi Solbiati,et al.  Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. , 2012, Radiology.

[27]  M. Gonen,et al.  Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer , 2012, Cancer.

[28]  W. Hohenberger,et al.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Ledermann,et al.  Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  G. Fiorentini,et al.  A systematic review of FOLFOXIRI chemotherapy for the first‐line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[31]  C. V. van Kuijk,et al.  Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. , 2011, The British journal of radiology.

[32]  P. Wust,et al.  Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[33]  G. Otto,et al.  Radiofrequency Ablation as First-Line Treatment in Patients With Early Colorectal Liver Metastases Amenable to Surgery , 2010, Annals of surgery.

[34]  P. Levendag,et al.  Stereotactic body radiation therapy for colorectal liver metastases , 2010, The British journal of surgery.

[35]  W. Lees,et al.  Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation , 2009, European Radiology.

[36]  L. Crinò,et al.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  K. Syrigos,et al.  FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) , 2006, British Journal of Cancer.

[38]  U. Neumann,et al.  Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. , 2018, European journal of cancer.

[39]  J. Debus,et al.  Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. , 2004, Frontiers of radiation therapy and oncology.